Clinical Trials
19 trialsNCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT02125617 2026-01-14
uPARCRPC
Rigshospitalet, Denmark
Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT05276492 2025-10-03
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
University of Chicago
Phase 1 Terminated
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT04421222 2025-02-28
EPI-7386
ESSA Pharmaceuticals
Phase 1 Terminated
NCT05295927 2025-02-03
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Research & Development, LLC
Phase 1 Terminated
NCT04291664 2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Phase 1 Terminated
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT03649841 2023-10-26
Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
Phase 2 Terminated
NCT03999515 2023-09-28
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01681433 2022-07-11
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03827473 2020-06-25
ACADEMIC
University of Utah
Phase 2 Terminated
NCT01994590 2019-03-19
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01845792 2018-06-04
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT01735396 2017-05-12
Abiraterone Acetate Trial in African American Prostate Cancer Patients
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01913015 2017-04-28
Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02656615 2017-03-24
ABI-RE
Cantonal Hospital of St. Gallen
Phase 2 Terminated